← Back to Search

Behavioral Intervention

DREAM Intervention for Type 1 Diabetes (DREAM Trial)

N/A

Recruiting

Led By Jenise C Wong, MD, PhD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adolescent must have T1D of any duration, and be receiving diabetes care at UCSF, CHLA or UC Davis

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3-months, 6-months, 9-months, end of study 12 to 15-months

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to help Latinx adolescents with type 1 diabetes in California improve their glucose control by developing a virtual peer group intervention called DREAM. The intervention will focus on encouraging and supporting the use

Who is the study for?

This trial is for Latinx adolescents with Type 1 Diabetes in California who may benefit from better glucose control through the use of diabetes technology. The study aims to support these youths and their families in using insulin pumps and monitoring devices more effectively.

What is being tested?

The DREAM intervention, which stands for Device Use Reimagined Through Education And Mentorship, is being tested. It's a virtual peer group program designed to encourage Latinx adolescents with T1D to use diabetes technology more frequently.

What are the potential side effects?

Since this trial focuses on education and mentorship rather than medication or medical procedures, there are no direct side effects related to drugs or surgical interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a teenager with Type 1 Diabetes and get my care at UCSF, CHLA, or UC Davis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3-months, 6-months, 9-months, end of study 12 to 15-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3-months, 6-months, 9-months, end of study 12 to 15-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3-months, 6-months, 9-months, end of study 12 to 15-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Adolescent In Person Event Evaluation

Adolescent Online Group Evaluation

Adolescent Phase 2 Intervention Survey - "Feedback Survey"

+7 more

Secondary study objectives

Adolescent BenPump/Pod & BurPump/Pod

Adolescent Benefits and Burdens of CGM (BenCGM & BurCGM)

Adolescent Diabetes Distress Scale (DDS)

+6 more

Other study objectives

Diabetes Technology Use

Hemoglobin A1c

Number of participants completing rountine appointments

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

Virtual peer groups (VPGs) Six different VPGs topics will be offered on two dates (same topic) every 4-6 weeks, with topics rotating at 4-6 week intervals during their 12-month study participation period. In-Person Events Quarterly in-person events will be offered during their 12-month study participation period.

Group II: Comparator GroupActive Control1 Intervention

An equal number of eligible non-enrolled patients at each site will be selected and matched to the enrolled cohort based on age, language, HbA1c, insurance type, and diabetes technology use at a population level.

0 / 1Eligibility criteria met